Treatment of PCNSL With R-IDARAM and Intrathecal Immunochemotherapy
This study suggests that R-IDARAM combined with intrathecal immunochemotherapy may be high effective in primary central nervous system lymphoma (PCNSL) patients.
Primary Central Nervous System Lymphoma
DRUG: R-IDARAM plus intrathecal chemotherapy
Overall survival, 3 year Overall survival, 3 year Overall survival
The investigators will evaluate response rate, progression free survival (PFS), overall survival (OS), and toxicity in primary central nervous system lymphoma (PCNSL) after systemic and intrathecal immunochemotherapy with deferred radiotherapy.